Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Go back to Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
(NASDAQ: DARE) Delayed: 0.81 +0.03 (3.85%)
Previous Close $0.78    52 Week High
Open $0.82    52 Week Low
Day High $0.84    P/E N/A 
Day Low $0.80    EPS
Volume 279,935